Akero Therapeutics, Inc. (AKRO) shareholders beware: Grabar Law Firm is investigating claims on your behalf

Philadelphia, Pennsylvania – (Newsfile Corp. – September 30, 2024) – If you own shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) as of September 13, 2022 and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/contact Joshua Grabar at [email protected] or call 267-507-6085.

Grabar law firm is investigating whether Akero officers and directors breached their fiduciary duties to the company.

WHY: A recently filed securities fraud class action lawsuit alleges that Akero Therapeutics made false and/or misleading statements about certain of its officers and directors and/or failed to disclose to the investing public that: (i) approximately 20% of patients enrolled in its SYMMETRY trial had cryptogenic cirrhosis and did not have definite NASH at baseline; (ii) patients with cryptogenic liver cirrhosis included in the SYMMETRY trial did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the outcomes of patients with cryptogenic cirrhosis should be excluded from the calculation of secondary endpoints of NASH resolution; (iv) Akero had introduced a confounding factor into the design of the SYMMETRY trial that materially affected the potential results of the trial and increased the risk that the trial would not meet its primary endpoint; (v) the SYMMETRY study did not meet the U.S. Food & Drug Administration guidelines for testing a drug for the treatment of NASH cirrhosis because Akero had not ruled out possible causes of each patient’s cirrhosis other than NASH; and (vi) consequently, Akero had the nature of the SYMMETRY trial, its utility in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a success would, significantly misrepresent commercial treatment for NASH cirrhosis.

WHAT YOU CAN DO: Current Akero shareholders who have held Akero shares since September 13, 2022 can request corporate reforms, the return to the company of funds spent on litigation defense, and a court-approved incentive award at no cost to them.

If you would like to learn more about this topic, you are welcome to visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/contact Joshua Grabar at [email protected] or call us at 267-507-6085.

Attorney Advertising Disclaimer

To view the source version of this press release, please visit